CoChat

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Aducanumab: First Approval

Dhillon, Sohita · 2021 · Drugs

Abstract

Aducanumab (aducanumab-avwa; Aduhelm™) is a human, immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid β. It has been co-developed by Biogen and Eisai under license from Neurimmune for the treatment of Alzheimer's disease. In June 2021, aducanumab received its first approval in the USA for the treatment of Alzheimer's disease. According to the US FDA prescribing information, treatment should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied. Aducanumab is under regulatory review in Japan and in Europe. Its long-term safety and tolerability is being evaluated in a multinational phase 3b clinical study in patients with early Alzheimer's disease (mild cognitive impairment and mild Alzheimer's disease). This article summarizes the milestones in the development of aducanumab leading to this first approval for Alzheimer's disease.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40265-021-01569-z

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 14 references

Research works printed but not linked: 1

  1. Haeberlein SB, Salloway S, Aisen P, et al. Evaluation of aducanumab efficacy in early Alzheimer’s disease [oral presentation]. AD/PD 2021, Virtual Conference. 2021.

Cited by

See all 293

Metadata

Authors
Dhillon, S.
Affiliations
Springer Nature (New Zealand) (NZ)
Corresponding author
Dhillon, Sohita
Venue
Drugs
Published
2021-07-29
Volume
81
Issue
12
Pages
1437-1443
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
OpenAlex
W3185184038
Cited by
293
References
14
Citations by year
2026: 32 · 2025: 51 · 2024: 83 · 2023: 68 · 2022: 50 · 2021: 9
FWCI
32.99
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
aducanumab, Alzheimer's disease, amyloid-beta, anti-amyloid monoclonal antibodies, FDA approval, drug development milestones, mild cognitive impairment, mild dementia, long-term safety and tolerability
MeSH terms
Alzheimer Disease, Humans, Amyloid beta-Peptides, Cognitive Dysfunction, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aducanumab: First Approval. https://app.cochat.ai/papers/10.1007/s40265-021-01569-z
The paper
Dhillon, S. (2021). Aducanumab: First Approval. Drugs. https://doi.org/10.1007/s40265-021-01569-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.